Thioredoxin-interacting protein (TXNIP) plays an important role in glucose metabolism, and its expression is regulated by DNA methylation (DNAm). Although the association between TXNIP DNAm and type 2 diabetes mellitus has been demonstrated in studies with a cross-sectional design, prospective studies are needed. We therefore examined the association between TXNIP DNAm levels and longitudinal changes in glycemic traits by conducting a longitudinal study involving 169 subjects who underwent two health checkups in 2015 and 2019. We used a pyrosequencing assay to determine TXNIP DNAm levels in leukocytes (cg19693031). Logistic regression analyses were performed to assess the associations between dichotomized TXNIP DNAm levels and marked increases in glycemic traits. At four years, the TXNIP DNA hypomethylation group had a higher percentage of changes in fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) compared to those in the hypermethylation group. The adjusted odds ratios for FPG and HbA1c levels were significantly higher in the TXNIP DNA hypomethylation group than in the hypermethylation group. We found that TXNIP DNA hypomethylation at baseline was associated with a marked increase in glycemic traits. Leukocyte TXNIP DNAm status could potentially be used as an early biomarker for impaired glucose homeostasis.
硫氧还蛋白相互作用蛋白(TXNIP)在葡萄糖代谢中发挥着重要作用,其表达受 DNA 甲基化(DNAm)的调控。尽管横断面设计的研究已经证实了 TXNIP DNAm 与 2 型糖尿病之间的关系,但仍需进行前瞻性研究。因此,我们通过开展一项纵向研究,考察了TXNIP DNAm水平与血糖特征纵向变化之间的关联,该研究涉及2015年和2019年接受两次健康检查的169名受试者。我们采用热测序法测定白细胞中的TXNIP DNAm水平(cg19693031)。我们进行了逻辑回归分析,以评估二分TXNIP DNAm水平与血糖特征明显增加之间的关联。四年后,与高甲基化组相比,TXNIP DNA 低甲基化组的空腹血浆葡萄糖(FPG)和血红蛋白 A1c(HbA1c)的变化比例更高。TXNIP DNA 低甲基化组的 FPG 和 HbA1c 水平调整后的几率明显高于高甲基化组。我们发现,基线TXNIP DNA低甲基化与血糖特征的明显增加有关。白细胞 TXNIP DNAm 状态有可能被用作葡萄糖稳态受损的早期生物标志物。
{"title":"Association between DNA methylation levels of thioredoxin-interacting protein (TXNIP) and changes in glycemic traits: a longitudinal population-based study.","authors":"Keisuke Maeda, Ryosuke Fujii, Hiroya Yamada, Eiji Munetsuna, Mirai Yamazaki, Yoshitaka Ando, Genki Mizuno, Hiroaki Ishikawa, Koji Ohashi, Yoshiki Tsuboi, Yuji Hattori, Yuya Ishihara, Nobuyuki Hamajima, Shuji Hashimoto, Koji Suzuki","doi":"10.1507/endocrj.EJ23-0629","DOIUrl":"10.1507/endocrj.EJ23-0629","url":null,"abstract":"<p><p>Thioredoxin-interacting protein (TXNIP) plays an important role in glucose metabolism, and its expression is regulated by DNA methylation (DNAm). Although the association between TXNIP DNAm and type 2 diabetes mellitus has been demonstrated in studies with a cross-sectional design, prospective studies are needed. We therefore examined the association between TXNIP DNAm levels and longitudinal changes in glycemic traits by conducting a longitudinal study involving 169 subjects who underwent two health checkups in 2015 and 2019. We used a pyrosequencing assay to determine TXNIP DNAm levels in leukocytes (cg19693031). Logistic regression analyses were performed to assess the associations between dichotomized TXNIP DNAm levels and marked increases in glycemic traits. At four years, the TXNIP DNA hypomethylation group had a higher percentage of changes in fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) compared to those in the hypermethylation group. The adjusted odds ratios for FPG and HbA1c levels were significantly higher in the TXNIP DNA hypomethylation group than in the hypermethylation group. We found that TXNIP DNA hypomethylation at baseline was associated with a marked increase in glycemic traits. Leukocyte TXNIP DNAm status could potentially be used as an early biomarker for impaired glucose homeostasis.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":"593-601"},"PeriodicalIF":1.3,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-31DOI: 10.1507/endocrj.ej24-0142
Ema Toyokuni, Hiroshi Okada, Goji Hasegawa, Mayuko Kadono, Sayaka Kato, Mari Yoneda, Michiaki Fukui
When a neuroendocrine tumor with abundant blood flow is located in the pancreatic tail, it is difficult to distinguish it from accessory spleen. The patient was a 71-year-old woman who was admitted with impaired consciousness and hypoglycemia, raising suspicion of insulinoma. The selective arterial calcium injection test suggested a lesion in the pancreatic tail. Contrast-enhanced computed tomography and magnetic resonance imaging (MRI) showed a mass in the splenic hilum; however, its continuity with the pancreas was unclear. Contrast-enhanced MRI using super paramagnetic iron oxide (SPIO) showed no SPIO uptake in the splenic hilar mass. SPIO contrast-enhanced MRI is considered useful for differentiating pancreatic endocrine tumors from paraspleen tumors.